# To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.

> **NCT04831996** · PHASE1 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 48 (actual)

## Conditions studied

- Advanced Malignancies

## Interventions

- **DRUG:** parsaclisib

## Key facts

- **NCT ID:** NCT04831996
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-04
- **Primary completion:** 2022-07-08
- **Final completion:** 2022-07-08
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2022-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04831996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04831996, "To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04831996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*